A study to understand more about why chemotherapy to treat lung cancer can stop working (CHEMORES)
Cancer type:
Status:
Phase:
This study will look for changes in blood and tissue samples before and after treatment for lung cancer. This is to try to find out how cancer cells stop themselves being harmed by treatment.
More about this trial
Doctors may use surgery, radiotherapy, chemotherapy or another type of drug that targets lung cancer to treat this disease. Your treatment will depend on your type and stage of lung cancer. If you have non small cell lung cancer, you may have a combination of these.
We know from research that cancer cells can become 'resistant’ to treatment. In lung cancer for example, cancer cells can sometimes reduce the concentration of the drug inside them, and repair DNA damage. And, develop changes in the genes in cancer cells that prevent the treatment from working.
Understanding why resistance happens will help develop improved treatment for lung cancer. This study is looking at genes and proteins in cancer cells in the blood and cancer tissue of people having lung cancer treatment such as chemotherapy containing platinum drugs. The main aim of this study is to find out why lung cancer often becomes resistant to treatment.
You will not get any direct benefit from taking part in this study, and it will not change your treatment in any way. But the results of the study will be used to help people with cancer in the future.
Who can enter
You can enter this study if you
- Have small cell lung cancer, small cell carcinoma outside the lung or non small cell lung cancer that is stage 3 or 4
- Are due to have chemotherapy, immunotherapy or another type of drug that targets lung cancer such as erlotinib, gefitinib or crizotinib
- Have had a small sample of cancer tissue (a biopsy) removed from your lung, or you would be willing to have some tissue removed if appropriate
- Are well enough to take part
You cannot enter this study if you are having treatment as part of a clinical trial . If your trial team are happy for you to also take part in this study, you can still take part.
Trial design
This study will recruit over 1,000 people. Everyone will give a blood sample
- before treatment
- during treatment
- if your treatment changes
- if the cancer shows signs of resistance to the treatment
This could be up to 8 teaspoons of blood. The exact number of blood samples the team collect will vary between each person.
By taking part you give permission for the study team to
- Use a sample of stored tissue taken from a previous biopsy
- Take information from your hospital notes, including about your disease and treatment
- Send the samples to be studied by other member of the research team in Europe
You do not have to join the next part of the study if you don’t want to. You will give one or more samples of cancer tissue (biopsy) or fluid from your cancer tissue (fine needle aspirate) if your cancer can be easily reached to do this.
The study team will look at these samples to find out how genes and proteins in cancer tissue change after treatment. They will then check these findings against results from the stored samples and medical information.
Throughout the study you will remain under the care of your regular cancer specialist.
Hospital visits
Where possible, you will give your study blood samples at the same time as your routine blood samples.
If you give any extra biopsies or fine needle aspirates, you may need to make extra hospitals visits to the Christie Hospital in Manchester. The samples would be taken before, during treatment and if your cancer comes back. The study team will tell you about any hospital visits you have to make.
Side effects
You may have a small bruise where you gave your blood sample.
If you have biopsies for the study, the side effects will depend on the type of biopsy you have. You may have
- Pain or discomfort at the biopsy site (you will have local anaesthetic to help reduce this)
- Bleeding
- Bruising
- Sore throat (if you have a biopsy taken during a bronchoscopy)
Location
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Fiona Blackhall
Supported by
Experimental Cancer Medicine Centre (ECMC)
The Christie NHS Foundation Trust
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
